Status:
RECRUITING
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
Lead Sponsor:
Mayo Clinic
Conditions:
Type 1 Diabetes
Type 2 Diabetes
Eligibility:
All Genders
25-70 years
Phase:
PHASE2
Brief Summary
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are...
Detailed Description
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. This supports oth...
Eligibility Criteria
Inclusion
- Type 1 or type 2 diabetes treated with insulin
Exclusion
- Age \< 25 or \> 70 years.
- HbA1c \> 10.0%
- For female subjects: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Prior use of GLP-1 receptor agonists in the previous year.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Key Trial Info
Start Date :
October 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2029
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06976619
Start Date
October 3 2025
End Date
March 31 2029
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905